Thirty-seven-year-old Nick Asoian of Denver unsuccessfully fought Hodgkin’s Lymphoma using conventional cancer treatments for two years.  In 2008, while in New Zealand for a ski race, Nick was diagnosed with the condition. Two bone marrow transplants and two years of chemotherapy combined with radiation therapy didn’t bring his cancer to heel.

Nick Asoian. Image source:

A few years ago, the avid skier got wind of a clinical trial using T cell therapy at the Center for Cell and Gene Therapy at the Baylor College of Medicine in Texas. After speaking with Dr. Bollard and Vicky Torrano, the physicians conducting the trial, Asoian decided to give it a shot.

A Brother’s Help

Nick underwent 12 treatments over the course of two years, which consisted of taking his brother Nate’s blood and extracting the T cells. Technicians then engineered those cells to be resistant to the toxin emitted by Hodgkin’s.

After two years using the novel T cell therapy, the results have been nothing short of remarkable, as multiple PET scans have shown no evidence of the disease after his last infusion.

First-of-its-kind Trial

In a first-of-its-kind clinical trial, Baylor College of Medicine (BCM) evaluated the safety, survival and anti-tumor activity of tumor-targeted T cells in patients with Epstein-Barr Virus (EBV)-positive lymphoma, a type of cancer. The researchers published their results in the Journal of Clinical Oncology.

T cell therapy has shown promise in patients with chemotherapy-resistant lymphoma. Despite these advances, however, a large number of patients still respond poorly.

Lymphoma begins in the lymphocytes – the infection-fighting cells of the immune system. Lymphocytes are in the bone marrow, lymph nodes, spleen, thymus and other parts of the body. In lymphoma, the lymphocytes change and grow out of control.

The primary advantage of T cell therapy is that it is highly targeted to tumor cells, avoiding bystander damage. Patients have had successful responses with virtually no toxicity, unlike with conventional cancer treatments, such as radiation and chemotherapy.

Like most tumors, lymphomas suppress the immune system by secreting inhibitory chemicals. One of these inhibitory molecules, called TGFβ, inhibits the expansion and function of tumor-fighting T cells, limiting their ability to eradicate tumors.

The research team said this work exemplifies bench-to-bedside efforts and the power of virus-specific T cells to produce a significant patient response with little toxicity.

Dr. Cliona Rooney is the senior author of the study and a professor of pediatrics in the division of hematology and oncology at the Baylor College of Medicine, the Texas Children’s Hospital, and the Houston Methodist Hospital. Dr. Rooney described the treatment, saying, “We modified our EBV-specific T cells with a dominant-negative TGFβ receptor in which the intracellular signaling domain had been deleted. This mutant receptor can bind TGFβ but does not transmit an inhibitory signal and also blocks the inhibitory signaling of TGFβ through its normal receptor.”


The research team began to investigate this type of T cell therapy in 2002. Earlier studies showed that T cells expressing the dominant-negative TGFβ receptor could grow in the presence of TGFβ, while unmodified T cells failed to develop and died within two weeks. Later, the team evaluated the safety and efficacy of the strategy using animal models. The success of the T cell therapy in animal experiments led to the clinical trial.

“In an earlier clinical study of unmodified EBV-specific T cells, more than 50 percent of patients experienced complete remission, and tumor responses were observed in over 70 percent,” Dr. Rooney explained. “In the new study, patients who did not experience complete responses to unmodified EBVSTs had complete responses to the same T cells modified with the dominant negative TGF b receptor.”

Dr. Bollard is the first author of the study and director of the Children’s Research Institute’s Center for Cancer & Immunology Research and was at Baylor when the study was conducted.  Dr. Bollard says the results hold promise, adding, “These results come 18 years after this revolutionary approach was first conceptualized. While the study is small, its findings are encouraging for our patients’ families and for the cancer field.”

About Longevityfacts

We have teamed up with our friends at Longevityfacts and will be publishing some of their articles as part of an agreed syndication deal. This article originally appeared here at Longevityfacts.


“Gene-modified, virus-specific T cell therapy shows promise in treating lymphoma, with little toxicity.” Baylor College of Medicine. Jan 25, 2018 [BCM Press Release].

CategoryBlog, Research
About the author

Brady Hartman

Brady is the editor of the longevity focused blog and is an active advocate for rejuvenation biotechnology and geroscience.

Write a comment:


Your email address will not be published.

15 + 14 =

Privacy Policy / Terms Of Use

       Powered by MMD